Manipulation and exploitation of the tumour environment for therapeutic benefit.
We describe aspects of the tumour microenvironment that are available as targets for manipulation. In particular, the question asked is whether hypoxia in tumours is a problem to be overcome, or a physiological abnormality to be exploited? Bioreductive drugs require metabolic reduction to generate cytotoxic metabolites. This process is facilitated by appropriate reductases and the lower oxygen conditions present in solid tumours compared with normal tissues. Because of their specificity, bioreductive drugs are used to help answer this question. Other aspects of tumour physiology and biochemistry that may be exploited include tissue dependent reductase expression, pH and angiogenesis.
Stratford
I J
IJ
MRC Radiobiology Unit, Chilton, Didcot, UK.
Adams
G E
GE
Bremner
J C
JC
Cole
S
S
Edwards
H S
HS
Robertson
N
N
Wood
P J
PJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents